Dutasteride Lipid Composition for Sustained Release Without Precipitation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing dutasteride formulations require long-term administration to maintain efficacy, leading to low patient compliance due to precipitation and localized irritation at the administration site, limiting their effectiveness in treating benign prostatic hyperplasia and male pattern hair loss.
Innovation Solution
A composition containing dutasteride, lipid, and an organic solvent is developed to prevent precipitation and maintain a sustained release, ensuring a constant blood concentration for an extended period without causing local irritation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If dutasteride is administered as conventional oral tablets requiring daily intake, then the drug can maintain therapeutic effect, but patient compliance deteriorates due to the need for long-term continuous administration
Solution Approach 1:
The patent applies preliminary action by formulating dutasteride in a liposomal carrier system that pre-prepares the drug for sustained release. The liposomes are designed to maintain drug concentration over extended periods, eliminating the need for daily administration and improving patient compliance while maintaining therapeutic efficacy.
2Duration of action of moving object
If dutasteride concentration is maintained continuously in blood, then therapeutic effect is sustained, but precipitation and localized irritation occur at the administration site
Solution Approach 1:
The patent uses liposomes as an intermediary carrier system. The liposomal structure encapsulates dutasteride, preventing direct contact with tissues that would cause precipitation and irritation. This mediator allows sustained drug release into the bloodstream while protecting the administration site from harmful local effects.
Solution Approach 2:
The patent changes the physical and chemical parameters of drug delivery by transitioning from conventional tablets to liposomal formulation. This parameter change includes modifying solubility, release kinetics, and tissue interaction properties, enabling sustained blood concentration without precipitation or local irritation.
3Ease of manufacture
If conventional formulations are used, then manufacturing is simple, but the drug precipitates and causes localized irritation
Solution Approach 1:
The patent employs composite materials by combining dutasteride with liposomal carriers. This composite formulation maintains relative manufacturing simplicity while fundamentally solving the precipitation and irritation problems through the liposomal structure that controls drug release and prevents direct tissue contact.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition achieves improved patient compliance by maintaining dutasteride levels in the blood for over a month, reducing precipitation and irritation, and providing a safe, effective treatment for benign prostatic hyperplasia and male pattern hair loss.
Implementation Method 1
said composition continues a concentration of the drug in blood for a long period of time when being administered into the human body
Implementation Method 2
does not cause the precipitation of dutasteride in an administration site
Data Source
AI summary
A composition of the present invention relates to a composition comprising dutasteride, wherein said composition may maintain a constant concentration of dutasteride in blood and continuously release a drug thereof for a long period of time while not precipitating dutasteride in a solid form when being administered into the human body, and also has an excellent safety without causing local irritations in an administration site.